Q4 2019 13F Holders as of 12/31/2019
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
126M
-
Number of holders
-
146
-
Total 13F shares, excl. options
-
59M
-
Shares change
-
-3.11M
-
Total reported value, excl. options
-
$1.13B
-
Value change
-
-$54.7M
-
Put/Call ratio
-
1.29
-
Number of buys
-
84
-
Number of sells
-
-48
-
Price
-
$19.17
Significant Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) as of Q4 2019
166 filings reported holding KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share as of Q4 2019.
Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) has 146 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 59M shares
of 126M outstanding shares and own 46.62% of the company stock.
Largest 10 shareholders include Consonance Capital Management LP (6.13M shares), Avoro Capital Advisors LLC (5.9M shares), BlackRock Inc. (4.77M shares), Palo Alto Investors LP (4.6M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.79M shares), STATE STREET CORP (3.23M shares), VANGUARD GROUP INC (2.77M shares), D. E. Shaw & Co., Inc. (2.37M shares), Delphi Management Partners VIII, L.L.C. (2.26M shares), and CITADEL ADVISORS LLC (1.39M shares).
This table shows the top 146 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.